New Silkroutes Group Limited announced to signed a Memorandum of Understanding (MOU) with Huawei International Pte Ltd. to develop an artificial intelligence (AI) platform that can be used in genomics-driven healthcare, including building predictive models for cancer and other ailments. Under the MOU, NSG and Huawei will extensively explore a collaboration to use AI to establish breakthrough analyses into genomic data and develop predictive models for diagnoses, therapeutics and prognoses in oncology and genomics. Genomic medicine involves the study of a patient's DNA and how the information can be used to improve clinical care through better diagnosis and personalised treatment. With the advent of big data, AI can help speed up the analysis of vast amounts of genomic sequence data to ultimately allow doctors and patients to identify and manage conditions at the earliest possible stages. NSG's MOU with Huawei does not at this point involve any commitment of funding, and both parties will sign a binding agreement should they decide to take the collaboration to the next level.